Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down – Time to Sell?

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLFGet Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $15.40, but opened at $14.5595. Ono Pharmaceutical shares last traded at $14.5595, with a volume of 7,522 shares trading hands.

Analyst Ratings Changes

Separately, Zacks Research upgraded Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the stock has an average rating of “Strong Buy”.

Check Out Our Latest Research Report on OPHLF

Ono Pharmaceutical Stock Performance

The firm has a market capitalization of $6.84 billion, a price-to-earnings ratio of 13.87 and a beta of 0.33. The company has a 50-day moving average price of $14.63 and a 200-day moving average price of $14.82. The company has a quick ratio of 2.56, a current ratio of 3.02 and a debt-to-equity ratio of 0.10.

Ono Pharmaceutical Company Profile

(Get Free Report)

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.

Recommended Stories

Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.